Annals of Thoracic Medicine Official publication of the Saudi Thoracic Society, affiliated to King Saud University
 
Search Ahead of print Current Issue Archives Instructions Subscribe e-Alerts Login 
Home Email this article link Print this article Bookmark this page Decrease font size Default font size Increase font size
GUIDELINES
Year : 2008  |  Volume : 3  |  Issue : 6  |  Page : 100-103

Treatment for small-cell lung cancer


1 Riyadh Military Hospital, Riyadh, Saudi Arabia
2 King Abdulaziz Medical City, Riyadh, Saudi Arabia

Correspondence Address:
Ahmed Saadeen
Department of Oncology (Bldg 1), Riyadh Military Hospital, P.O. Box 7897, Riyadh 11159
Saudi Arabia
Login to access the Email id


Rights and Permissions

Small-cell lung cancer (SCLC) accounts for 13-20% of all lung cancers. Stongly associated with smoking and initially responsive to treatment, it results in death within 2-4 months without treatment. Limited-stage disease is treated with curative intent with chemotherapy and radiation therapy, with approximately 20% of patients achieving a cure. Extensive-stage disease is primarily treated with chemotherapy and has a high initial response rate of 60-70% but the median survival is only 10 months. All patients achieving a complete remission should be offered prophylactic cranial irradiation. Relapsed or refractory SCLC has a uniformly poor prognosis.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2843    
    Printed164    
    Emailed1    
    PDF Downloaded559    
    Comments [Add]    

Recommend this journal